When will Ritlecitinib be available in China?

In June 2023, Ritlecitinib (Ritlecitinib) has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) ) has also accepted a Marketing Authorization Application (MAA) for rituxitinib, sold under the trade name Litfulo, a treatment for severe alopecia areata (AA) in adolescents and adults aged 12 years and older, which can affect people of any age, gender, race or ethnicity and can cause considerable burden beyond hair loss. It is understood that the original drug of ritixitinib has been approved for marketing by the State Food and Drug Administration in 2023, with the trade name of Rofenox. However, due to the short time, the specific price is not yet clear, and it has not been included in medical insurance.